Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement

Wilson I. Gonsalves; Francis K. Buadi; Sikander Ailawadhi; P. Leif Bergsagel; Asher A. Chanan Khan; David Dingli; Angela Dispenzieri; Rafael Fonseca; Susan R. Hayman; Prashant Kapoor; Taxiarchis V. Kourelis; Martha Q. Lacy; Jeremy T. Larsen; Eli Muchtar; Craig B. Reeder; Taimur Sher; A. Keith Stewart; Rahma Warsame; Ronald S. Go; Robert A. Kyle; Nelson Leung; Yi Lin; John A. Lust; Stephen J. Russell; Stephen R. Zeldenrust; Amie L. Fonder; Yi L. Hwa; Miriam A. Hobbs; Angela A. Mayo; William J. Hogan; S. Vincent Rajkumar; Shaji K. Kumar; Morie A. Gertz; Vivek Roy

doi:10.1038/s41409-018-0264-8

Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement

Wilson I. Gonsalves, Francis K. Buadi, Sikander Ailawadhi, P. Leif Bergsagel, Asher A. Chanan Khan, David Dingli, Angela Dispenzieri, Rafael Fonseca, Susan R. Hayman, Prashant Kapoor, Taxiarchis V. Kourelis, Martha Q. Lacy, Jeremy T. Larsen, Eli Muchtar, Craig B. Reeder, Taimur Sher, A. Keith Stewart, Rahma Warsame, Ronald S. Go, Robert A. KyleNelson Leung, Yi Lin, John A. Lust, Stephen J. Russell, Stephen R. Zeldenrust, Amie L. Fonder, Yi L. Hwa, Miriam A. Hobbs, Angela A. Mayo, William J. Hogan, S. Vincent Rajkumar, Shaji K. Kumar, Morie A. Gertz, Vivek Roy

Research output: Contribution to journal › Review article › peer-review

38 Scopus citations

Abstract

Over the last two decades, the utilization of various novel therapies in the upfront or salvage settings has continued to improve survival outcomes for patients with Multiple Myeloma (MM). Thus, the conventional role for hematopoietic stem cell transplantation (HSCT) in MM either in the form of an autologous stem cell transplant (ASCT) or an allogeneic stem cell transplant (Allo-SCT) warrants re-evaluation, given the aforementioned clinical advances. Here, we present a consensus statement of our multidisciplinary group of over 30 Mayo Clinic physicians with a special interest in the care of patients with MM and provide evidence-based recommendations on the use of HSCT in MM. We specifically address topics that include the role and timing of an ASCT for MM in the era of novel agents, eligibility for an ASCT, post-ASCT consolidation, and maintenance options, and finally the utility of an upfront tandem ASCT, salvage second ASCT, and an allo-SCT in MM.

Original language	English (US)
Pages (from-to)	353-367
Number of pages	15
Journal	Bone Marrow Transplantation
Volume	54
Issue number	3
DOIs	https://doi.org/10.1038/s41409-018-0264-8
State	Published - Mar 1 2019

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1038/s41409-018-0264-8

Cite this

Gonsalves, W. I., Buadi, F. K., Ailawadhi, S., Bergsagel, P. L., Chanan Khan, A. A., Dingli, D., Dispenzieri, A., Fonseca, R., Hayman, S. R., Kapoor, P., Kourelis, T. V., Lacy, M. Q., Larsen, J. T., Muchtar, E., Reeder, C. B., Sher, T., Stewart, A. K., Warsame, R., Go, R. S., ... Roy, V. (2019). Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplantation, 54(3), 353-367. https://doi.org/10.1038/s41409-018-0264-8

Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. / Gonsalves, Wilson I.; Buadi, Francis K.; Ailawadhi, Sikander et al.
In: Bone Marrow Transplantation, Vol. 54, No. 3, 01.03.2019, p. 353-367.

Research output: Contribution to journal › Review article › peer-review

Gonsalves, WI, Buadi, FK, Ailawadhi, S , Bergsagel, PL , Chanan Khan, AA , Dingli, D , Dispenzieri, A , Fonseca, R, Hayman, SR, Kapoor, P , Kourelis, TV , Lacy, MQ, Larsen, JT, Muchtar, E, Reeder, CB, Sher, T, Stewart, AK, Warsame, R, Go, RS, Kyle, RA, Leung, N, Lin, Y, Lust, JA, Russell, SJ, Zeldenrust, SR, Fonder, AL, Hwa, YL, Hobbs, MA, Mayo, AA, Hogan, WJ , Rajkumar, SV , Kumar, SK , Gertz, MA & Roy, V 2019, 'Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement', Bone Marrow Transplantation, vol. 54, no. 3, pp. 353-367. https://doi.org/10.1038/s41409-018-0264-8

@article{87423d36eb814d19ac81a60fdcb8e85e,

title = "Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement",

abstract = "Over the last two decades, the utilization of various novel therapies in the upfront or salvage settings has continued to improve survival outcomes for patients with Multiple Myeloma (MM). Thus, the conventional role for hematopoietic stem cell transplantation (HSCT) in MM either in the form of an autologous stem cell transplant (ASCT) or an allogeneic stem cell transplant (Allo-SCT) warrants re-evaluation, given the aforementioned clinical advances. Here, we present a consensus statement of our multidisciplinary group of over 30 Mayo Clinic physicians with a special interest in the care of patients with MM and provide evidence-based recommendations on the use of HSCT in MM. We specifically address topics that include the role and timing of an ASCT for MM in the era of novel agents, eligibility for an ASCT, post-ASCT consolidation, and maintenance options, and finally the utility of an upfront tandem ASCT, salvage second ASCT, and an allo-SCT in MM.",

author = "Gonsalves, {Wilson I.} and Buadi, {Francis K.} and Sikander Ailawadhi and Bergsagel, {P. Leif} and {Chanan Khan}, {Asher A.} and David Dingli and Angela Dispenzieri and Rafael Fonseca and Hayman, {Susan R.} and Prashant Kapoor and Kourelis, {Taxiarchis V.} and Lacy, {Martha Q.} and Larsen, {Jeremy T.} and Eli Muchtar and Reeder, {Craig B.} and Taimur Sher and Stewart, {A. Keith} and Rahma Warsame and Go, {Ronald S.} and Kyle, {Robert A.} and Nelson Leung and Yi Lin and Lust, {John A.} and Russell, {Stephen J.} and Zeldenrust, {Stephen R.} and Fonder, {Amie L.} and Hwa, {Yi L.} and Hobbs, {Miriam A.} and Mayo, {Angela A.} and Hogan, {William J.} and Rajkumar, {S. Vincent} and Kumar, {Shaji K.} and Gertz, {Morie A.} and Vivek Roy",

note = "Publisher Copyright: {\textcopyright} 2018, The Author(s).",

year = "2019",

month = mar,

day = "1",

doi = "10.1038/s41409-018-0264-8",

language = "English (US)",

volume = "54",

pages = "353--367",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma

T2 - a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement

AU - Gonsalves, Wilson I.

AU - Buadi, Francis K.

AU - Ailawadhi, Sikander

AU - Bergsagel, P. Leif

AU - Chanan Khan, Asher A.

AU - Dingli, David

AU - Dispenzieri, Angela

AU - Fonseca, Rafael

AU - Hayman, Susan R.

AU - Kapoor, Prashant

AU - Kourelis, Taxiarchis V.

AU - Lacy, Martha Q.

AU - Larsen, Jeremy T.

AU - Muchtar, Eli

AU - Reeder, Craig B.

AU - Sher, Taimur

AU - Stewart, A. Keith

AU - Warsame, Rahma

AU - Go, Ronald S.

AU - Kyle, Robert A.

AU - Leung, Nelson

AU - Lin, Yi

AU - Lust, John A.

AU - Russell, Stephen J.

AU - Zeldenrust, Stephen R.

AU - Fonder, Amie L.

AU - Hwa, Yi L.

AU - Hobbs, Miriam A.

AU - Mayo, Angela A.

AU - Hogan, William J.

AU - Rajkumar, S. Vincent

AU - Kumar, Shaji K.

AU - Gertz, Morie A.

AU - Roy, Vivek

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Over the last two decades, the utilization of various novel therapies in the upfront or salvage settings has continued to improve survival outcomes for patients with Multiple Myeloma (MM). Thus, the conventional role for hematopoietic stem cell transplantation (HSCT) in MM either in the form of an autologous stem cell transplant (ASCT) or an allogeneic stem cell transplant (Allo-SCT) warrants re-evaluation, given the aforementioned clinical advances. Here, we present a consensus statement of our multidisciplinary group of over 30 Mayo Clinic physicians with a special interest in the care of patients with MM and provide evidence-based recommendations on the use of HSCT in MM. We specifically address topics that include the role and timing of an ASCT for MM in the era of novel agents, eligibility for an ASCT, post-ASCT consolidation, and maintenance options, and finally the utility of an upfront tandem ASCT, salvage second ASCT, and an allo-SCT in MM.

AB - Over the last two decades, the utilization of various novel therapies in the upfront or salvage settings has continued to improve survival outcomes for patients with Multiple Myeloma (MM). Thus, the conventional role for hematopoietic stem cell transplantation (HSCT) in MM either in the form of an autologous stem cell transplant (ASCT) or an allogeneic stem cell transplant (Allo-SCT) warrants re-evaluation, given the aforementioned clinical advances. Here, we present a consensus statement of our multidisciplinary group of over 30 Mayo Clinic physicians with a special interest in the care of patients with MM and provide evidence-based recommendations on the use of HSCT in MM. We specifically address topics that include the role and timing of an ASCT for MM in the era of novel agents, eligibility for an ASCT, post-ASCT consolidation, and maintenance options, and finally the utility of an upfront tandem ASCT, salvage second ASCT, and an allo-SCT in MM.

UR - http://www.scopus.com/inward/record.url?scp=85049630770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049630770&partnerID=8YFLogxK

U2 - 10.1038/s41409-018-0264-8

DO - 10.1038/s41409-018-0264-8

M3 - Review article

C2 - 29988062

AN - SCOPUS:85049630770

SN - 0268-3369

VL - 54

SP - 353

EP - 367

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 3

ER -

Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this